JP2020537525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537525A5 JP2020537525A5 JP2020521290A JP2020521290A JP2020537525A5 JP 2020537525 A5 JP2020537525 A5 JP 2020537525A5 JP 2020521290 A JP2020521290 A JP 2020521290A JP 2020521290 A JP2020521290 A JP 2020521290A JP 2020537525 A5 JP2020537525 A5 JP 2020537525A5
- Authority
- JP
- Japan
- Prior art keywords
- vector according
- monkey
- adenovirus vector
- replicative
- monkey adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572927P | 2017-10-16 | 2017-10-16 | |
| US62/572,927 | 2017-10-16 | ||
| PCT/EP2018/078206 WO2019076877A1 (en) | 2017-10-16 | 2018-10-16 | ADENOVIRAL VECTORS FOR REPLICATION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020537525A JP2020537525A (ja) | 2020-12-24 |
| JP2020537525A5 true JP2020537525A5 (enExample) | 2022-06-20 |
Family
ID=63965644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521290A Pending JP2020537525A (ja) | 2017-10-16 | 2018-10-16 | 複製能力のあるアデノウイルスベクター |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11268108B2 (enExample) |
| EP (1) | EP3697899A1 (enExample) |
| JP (1) | JP2020537525A (enExample) |
| KR (1) | KR20200066349A (enExample) |
| CN (1) | CN111655847A (enExample) |
| AR (1) | AR113450A1 (enExample) |
| AU (1) | AU2018351308B2 (enExample) |
| BR (1) | BR112020007238A2 (enExample) |
| CA (1) | CA3079043A1 (enExample) |
| EA (1) | EA202090700A1 (enExample) |
| IL (1) | IL273753A (enExample) |
| MX (1) | MX2020003385A (enExample) |
| SG (1) | SG11202003058UA (enExample) |
| WO (1) | WO2019076877A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113966228A (zh) | 2019-06-11 | 2022-01-21 | 葛兰素史密斯克莱生物公司 | 黏膜疫苗配制剂 |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| EP4150344A1 (en) | 2020-05-14 | 2023-03-22 | GlaxoSmithKline Biologicals SA | Viral biosensors |
| CN114591922A (zh) * | 2022-03-30 | 2022-06-07 | 长睿生物技术(成都)有限公司 | 一种表达狂犬病毒g蛋白的重组黑猩猩源腺病毒及其制备方法 |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083716A (en) * | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| HUE039908T2 (hu) | 2009-02-02 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk |
| EP2459716B1 (en) * | 2009-07-31 | 2016-08-17 | Paxvax, Inc. | Adenoviral-based vectors |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| GB201322851D0 (en) * | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| WO2016198621A1 (en) | 2015-06-12 | 2016-12-15 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
-
2018
- 2018-10-16 SG SG11202003058UA patent/SG11202003058UA/en unknown
- 2018-10-16 WO PCT/EP2018/078206 patent/WO2019076877A1/en not_active Ceased
- 2018-10-16 EA EA202090700A patent/EA202090700A1/ru unknown
- 2018-10-16 BR BR112020007238-9A patent/BR112020007238A2/pt not_active IP Right Cessation
- 2018-10-16 KR KR1020207013668A patent/KR20200066349A/ko not_active Withdrawn
- 2018-10-16 CN CN201880080955.9A patent/CN111655847A/zh active Pending
- 2018-10-16 MX MX2020003385A patent/MX2020003385A/es unknown
- 2018-10-16 US US16/756,376 patent/US11268108B2/en active Active
- 2018-10-16 JP JP2020521290A patent/JP2020537525A/ja active Pending
- 2018-10-16 CA CA3079043A patent/CA3079043A1/en active Pending
- 2018-10-16 EP EP18792880.9A patent/EP3697899A1/en active Pending
- 2018-10-16 AU AU2018351308A patent/AU2018351308B2/en not_active Expired - Fee Related
- 2018-10-16 AR ARP180103004A patent/AR113450A1/es not_active Application Discontinuation
-
2020
- 2020-04-01 IL IL273753A patent/IL273753A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Travieso et al. | The use of viral vectors in vaccine development | |
| Humphreys et al. | Novel viral vectors in infectious diseases | |
| Kosinska et al. | Therapeutic vaccination for chronic hepatitis B | |
| Mühlebach | Vaccine platform recombinant measles virus | |
| JP7326157B2 (ja) | Ｈｂｖワクチン | |
| AU2025271193A1 (en) | Vaccines against Hepatitis B virus | |
| Bråve et al. | Vaccine delivery methods using viral vectors | |
| Clarke et al. | Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations | |
| JP2021519791A5 (enExample) | ||
| Hasanpourghadi et al. | COVID-19 vaccines based on adenovirus vectors | |
| JP2017515508A5 (enExample) | ||
| JP2020516264A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| Reynolds et al. | Virus-like vesicle-based therapeutic vaccine vectors for chronic hepatitis B virus infection | |
| Cobleigh et al. | A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose | |
| Vignuzzi et al. | Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein | |
| Cobleigh et al. | The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate | |
| Conforti et al. | Are genetic vaccines the right weapon against COVID-19? | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| Moreno et al. | Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge | |
| Flaxman et al. | Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse | |
| Penza et al. | The long-lasting enigma of polycytidine (polyC) tract | |
| JP2021500880A5 (enExample) | ||
| Hanke | New vector and vaccine platforms: mRNA, DNA, viral vectors | |
| Cervantes-Barragan et al. | Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity |